Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-25T17:14:15.714Z Has data issue: false hasContentIssue false
  • English
  • Français

Alternative initiation regimen of paliperidone palmitate long-acting injectable

Published online by Cambridge University Press:  01 September 2022

I.E. Menendez Gil ,
S.L. Romero Guillena  and
B.O. Plasencia Garcia De Diego
I.E. Menendez Gil*
Affiliation:
Virgen del Rocio Hospital, Psychiatry, Seville, Spain
S.L. Romero Guillena
Affiliation:
UGC Salud Mental Virgen Macarena,, Psychiatry, seville, Spain
B.O. Plasencia Garcia De Diego
Affiliation:
Virgen del Rocio Hospital, Psychiatry, Seville, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Long-acting injectable antipsychotics (LAIs) hold an important place in the treatment of psychosis. Knowledge of the best way to administer LAIs is important to maximize the efficacy and minimize the side-effects

Objectives

To assess the effectiveness of flexible doses of palmitate paliperidone long-acting injectable (PPLAI) against standard doses in initiation regimen in the subset of acutely hospitalized patients with schizophrenia and other psychosis

Methods

Retrospective, noninterventional study. Group of initiation regimen: A)“Standard-doses” (recommended PPLAI initiation regimen: 150mg-Day-1 and 100mg-Day-8±4days), B)“Low-doses” (any dosage lower than the Standard-dose) C)“High-doses” (150mg-Day-1 and 150mg-Day-8±4days) Effectiveness was measured with the number of psychiatric hospital admission and psychiatric emergency visit 6-months post-discharge. Length of stay of the index hospitalization, adherence to treatment and adverse events was confirmed in the medical record. Concomitant use of biperiden was recorded.

Results

51 patients were included. We found no statistically differences in study variables between groups (Table-1). Table-1.

Standard doses(n=31)Low-doses(n=13)High-doses(n=7)
Length of stay mean±sd17.23±13.0913.77±9.0217±10.55
No psychiatric hospitalizations 6-month post-discharge, %patients( n)71%(n=22)84.6%(n=11)85.7%(n=6)
No psychiatric emergency visits 6-month post-discharge, %patients(n)61.3%(n=19)69.2%(n=9)85.7%(n=6)
Prescription of biperiden 6-month post-discharge, %patients(n)13.3%(n=4)0%(n=0)14.3%(n=1)
Adherence to treatment 6-month post-discharge, %patients(n)80.6%(n=25)84.61%(n=11)57.1%(n=4)

Conclusions

No differences were found in the effectiveness of flexible-doses in PPLAI initiation regimen. The use of low doses of PPLAI could keep the efficacy of the standard dose with a better side effect profile and treatment adherence. The strength of the conclusion is limited by the design and the number of patients.

Disclosure

No significant relationships.

Keywords

schizophréniapaliperidone palmitate long-actingantipsychoticPsychosis
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S284 - S285
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.